Skip to content
Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
Biotechnology Innovation Organization (BIO) member companies and CEOs sent a letter to congressional leaders urging them to pass the bipartisan ORPHAN Cures Act and […]
CEOs ask Congress to pass ORPHAN Cures Act Read More »
As the 13th Ministerial Conference of the World Trade Organization (WTO) kicks off (Feb. 26-29), the expansion of the COVID-19 IP waiver remains a
Why the WTO should focus on addressing trade-related aspects of pandemic preparedness Read More »
On February 13, the New Mexico legislature passed a clean fuel standard—which the Biotechnology Innovation Organization (BIO) has long advocated for. The Clean Transportation
New Mexico legislature passes clean fuel standard Read More »
Contention over the Bayh-Dole march-in rights provision is in the news again. The National Institute of Standards and Technology (NIST) proposes using the process
BIO comments on NIST proposal to use march-in rights for price controls Read More »
The U.S. Trade Representative (USTR) needs to call out worldwide intellectual property deficiencies that harm U.S. biotech innovation—and they must not support a proposed
BIO report to USTR on global IP threats warns against TRIPS waiver Read More »
A bipartisan amendment to the Inflation Reduction Act (IRA), introduced in the House on January 31, would fix the law’s small molecule “pill penalty”
EPIC Act would fix IRA’s ‘pill penalty’ for small molecule drugs Read More »
“If you want to go fast, go alone,” said Interim Dean of UCLA’s Division of Social Sciences, Abel Valenzuela Jr., giving opening remarks at
When Medicine Stops Saving Us: The Antimicrobial Resistance Crisis Read More »
Vaccines have changed the course of human history as we know it. Since the first vaccine was discovered in the late 1700s, vaccine technology
What does the vaccine pipeline look like – and how can we strengthen it? Read More »
After the Food and Drug Administration (FDA) approved Gilead’s HIV/AIDS drug in 2001, the firm gained FDA approval for a second drug in 2015.
BIO says suit over speed of drug development is threat to innovation and new cures Read More »
The wait is finally over as the Biotechnology Innovation Organization (BIO) taps John F. Crowley, a longtime leader and tireless patient advocate in the
BIO names John F. Crowley as new President & CEO Read More »
